Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer, with its lead product Tavalisse (fostamatinib) approved for immune thrombocytopenia (ITP) in the US and Europe. The company generates revenue primarily from Tavalisse sales while advancing a pipeline targeting SYK and IRAK pathways. Recent 53% revenue growth and transition to profitability reflect commercial execution in the rare disease ITP market, though the small $600M market cap indicates early-stage commercial risk.
Rigel operates a focused commercial model selling Tavalisse directly to specialty pharmacies and hematology centers for chronic immune thrombocytopenia, a rare bleeding disorder affecting ~60,000 diagnosed US patients. The 89.6% gross margin reflects typical specialty pharma economics with low manufacturing costs relative to pricing power in orphan indications. Revenue scales through market penetration (currently estimated 15-20% of eligible ITP patients), duration of therapy (chronic treatment), and potential label expansions. The company monetizes ex-US rights through partnerships (Grifols in Europe, Kissei in Japan) to minimize infrastructure costs while retaining high-margin US economics.
Tavalisse quarterly prescription trends and net revenue per prescription (pricing/gross-to-net dynamics)
Clinical trial readouts for pipeline candidates targeting warm autoimmune hemolytic anemia (AIHA) and other hematologic indications
Partnership announcements or milestone achievements (ex-US commercialization, new indication licensing)
FDA regulatory decisions on label expansions or new molecular entities from SYK/IRAK inhibitor platform
Cash runway updates and financing events given biotech sector capital market volatility
Orphan drug market concentration risk - entire commercial model depends on single approved product (Tavalisse) in narrow ITP indication with ~3,000-4,000 active US patients, creating binary revenue exposure to competitive entry or safety issues
Regulatory pathway uncertainty for pipeline expansion - SYK inhibitor mechanism faces scrutiny on immunosuppression risks, potentially limiting label breadth for autoimmune indications beyond ITP
Reimbursement pressure on specialty pharmaceuticals - payers increasingly challenge high-cost rare disease therapies, and ITP treatment landscape includes cheaper corticosteroids and TPO agonists as alternatives
Established ITP competitors include Novartis' Promacta (eltrombopag) and Amgen's Nplate (romiplostim) with longer safety track records and broader physician familiarity, limiting Tavalisse to third/fourth-line positioning
Pipeline competition in autoimmune hematology from larger biotechs (Argenx, Principia/Sanofi, UCB) with deeper resources for clinical development and commercial execution
Biosimilar and generic erosion risk if mechanism-of-action patents face challenges, though composition-of-matter protection extends through early 2030s
Limited financial cushion despite profitability - $600M market cap with biotech-typical cash burn volatility means adverse clinical trial results or commercial stumbles could quickly necessitate dilutive financing
Royalty obligations to partners and milestone payment liabilities could strain cash flow if pipeline advances require upfront payments before revenue materialization
low - Rare disease treatments for serious bleeding disorders exhibit minimal GDP sensitivity as patients require therapy regardless of economic conditions. ITP is a chronic, potentially life-threatening condition where treatment decisions are clinically driven rather than discretionary. However, payer budget pressures during recessions could marginally impact reimbursement negotiations and prior authorization approval rates.
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of future pipeline assets, disproportionately impacting early-stage biotech valuations, and (2) tighter financial conditions reduce access to growth capital for clinical development and commercial expansion. The company's transition to profitability (9.8% net margin) reduces financing dependency versus cash-burning peers, but equity valuation multiples remain rate-sensitive given growth stock classification.
Minimal direct credit exposure. The company operates with 0.52x debt/equity and 2.28x current ratio, indicating conservative balance sheet. Revenue comes from specialty pharmacy distributors and European partners with strong credit profiles. However, broader healthcare credit conditions affect payer reimbursement stability and hospital/clinic purchasing budgets for specialty medications.
growth - The 68.7% one-year return despite recent pullback attracts momentum and biotech growth investors focused on commercial inflection stories. The 53% revenue growth and transition to profitability appeal to investors seeking early-stage commercial biotechs with validated products and pipeline optionality. High ROE (204.7%) and ROA (52.2%) metrics reflect small equity base and recent profitability, attracting quantitative screens for quality growth at reasonable valuation (2.3x P/S, 5.2x EV/EBITDA versus biotech peer averages).
high - Small-cap biotech with single-product revenue concentration exhibits elevated volatility around clinical catalysts, quarterly earnings, and sector rotation. The -17.7% three-month decline demonstrates sensitivity to biotech sector sentiment and risk-off flows. Binary clinical trial outcomes and regulatory decisions create event-driven volatility spikes typical of specialty pharma companies with concentrated pipelines.
